Background: Type 2 diabetes is contemporarily a major social and epidemiological problem and among others is a strong risk factor for cardiovascular diseases. Pentraxin 3 a potential early biomarker of the atherrosclerosis, is an acute phase reactant produced by the peripheral tissues where the inflammation takes place. The aim of this study was to assess PTX3 plasma levels in metabolic syndrome patients compared to control subjects and their potential associations with anthropometric and clinical components of the syndrome as well as with carotid artery intima-media thickness (cIMT), a marker of subclinical atherosclerosis. Methods: This study was conducted on 58 type 2 diabetic patients(34 men and 24 women ) as well as 30 age and sex matched non diabetic control subjects (12 men and 18 women ) the following tests were done FBS , lipid profile (Total serum cholesterol, triglyceride level and HDL cholesterol level). The LDL cholesterol level was estimated .In addition, we performed basic biochemical blood analysis (ALT,AST,CBC and TSH), Hemoglobin A1c and Plasma PTX3. Results: Mean plasma PTX3concentration turned out to be significantly higher in patients with history of myocardial infarction,CABG and PCI (p=0.01) . Conclusion: PTX3 was associated with outcomes in acute MI patients. PTX3 was associated with fatal events, and adverse clinical outcomes in heart failure patients |
